Anna Sitthi-Amorn

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 435 citations · Full text

Improving Patient Handoffs and Transitions through Adaptation and Implementation of I-PASS Across Multiple Handoff Settings

Lindsay Blazin, Anna Sitthi-Amorn, James M. Hoffman et al. · Pediatric Quality and Safety · 2020 · 69 citations · Full text

Daratumumab (DARA) + bortezomib/lenalidomide/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): Analysis of minimal residual disease (MRD) in the PERSEUS trial.

Paula Rodríguez‐Otero, Philippe Moreau, Meletios Α. Dimopoulos et al. · Journal of Clinical Oncology · 2024 · 22 citations

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · Blood · 2023 · 15 citations · Full text

Molecular Analysis of Central Nervous System Disease Spectrum in Childhood Acute Lymphoblastic Leukemia

Chindo Hicks, Anna Sitthi-Amorn, Jessica Douglas et al. · Clinical Medicine Insights Oncology · 2016 · 13 citations · Full text

Mixed-phenotype Acute Leukemia, Immunology, Pathology +20